To evaluate the contribution of KIR-HLA combinations to lung cancer risk, we analyzed the distribution of KIR genes and cognate HLA-I ligands within a group of 85 patients along with 178 HCs (Table 3). This evidence concerns the gene KIR3DL1 and lung cancer.